Autoimmune Thyroid & Cognition · · 25 min read · By

Dihexa for Hashimoto's & Hypothyroid Brain Fog: TPO Antibodies, the T3-BDNF-HGF Axis & NICE NG145 (2026 UK Review)

Hashimoto's thyroiditis is the most common autoimmune disease in the United Kingdom and the dominant cause of hypothyroidism in iodine-sufficient countries. A 2025 scoping review in Medicina places global prevalence at 4.8–25.8% in women and 0.9–7.9% in men, with women 2–7 times more likely to be affected. Memory disorders are reported by around a quarter of patients; more than 95% list forgetfulness, fatigue, sleepiness and loss of focus among their core symptoms. Roughly one in ten remain symptomatic on supposedly adequate levothyroxine. The biology is becoming clearer: thyroid hormone (particularly T3) directly upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus, and hypothyroidism reduces hippocampal neurogenesis, dendritic arborisation and synaptic plasticity. That biology overlaps with the proposed mechanism of Dihexa, a positive modulator of the HGF/c-Met synaptogenesis pathway. This 2026 review walks through TPO and thyroglobulin antibody biology, the T3-BDNF-HGF axis, the October 2025 NICE NG145 surveillance decision, the T3/liothyronine debate, Hashimoto's encephalopathy (SREAT), and where Dihexa actually sits in the evidence hierarchy — next to optimised levothyroxine, deficiency correction, and proper endocrine care.

Not medical advice. Dihexa (PNB-0408) is an unscheduled research chemical, not an approved treatment for Hashimoto's thyroiditis, hypothyroidism, brain fog or any other condition. Nothing on this page is medical advice. People with thyroid symptoms should be assessed by their GP and, where appropriate, an endocrinologist. Levothyroxine remains the NICE NG145-recommended first-line treatment for primary hypothyroidism. Read the full legal disclaimer.

Key Findings: Dihexa & Hashimoto's / Hypothyroid Brain Fog

  • UK scale: Hashimoto's is the most common autoimmune disease in iodine-sufficient countries. UK prevalence of treated hypothyroidism is around 2–3% of adults; subclinical hypothyroidism affects a further 4–10%. Up to 1 in 4 UK women carry positive TPO antibodies at some point in life on the British Thyroid Foundation figures.
  • Brain fog burden: Memory disorders 24%, slow thinking 22%, fatigue 18%; >95% of patients in surveys list forgetfulness, fatigue, sleepiness and lack of focus as core symptoms. Around 10% of levothyroxine-treated patients have persistent fog despite normal TSH.
  • Underlying biology: T3 directly drives BDNF expression in the hippocampus. Hypothyroidism reduces hippocampal neurogenesis and dendritic arborisation, with measurable ERP P300 latency and amplitude changes in Hashimoto's patients vs controls.
  • Why Dihexa is mechanistically interesting: Direct activation of the HGF/c-Met pathway drives synaptogenesis — the same end-point T3 deficiency disrupts. See Dihexa mechanism of action.
  • First-line care is levothyroxine optimisation: NICE NG145, reaffirmed by the October 2025 surveillance, retains levothyroxine as first-line. T3 (liothyronine) is not routinely recommended.
  • Closest clinical relative to Dihexa: Fosgonimeton (ATH-1017), an HGF/MET positive modulator — clinically tested, missed its Alzheimer's Phase 3 primary endpoint in 2024.
  • Human thyroid evidence for Dihexa: None. No registered or published clinical trial of Dihexa in any thyroid population.
  • Specific red flag: c-Met activation is oncogenically relevant in thyroid cancers (especially papillary), and TPO-antibody-positive nodular thyroid disease carries an elevated lifetime malignancy risk.
  • Bottom line: Optimise levothyroxine. Check ferritin, B12, folate, vitamin D, coeliac antibodies and sleep. Treat mood. Discuss T3 trial with an endocrinologist where indicated. Dihexa is mechanistically coherent and clinically unproven for thyroid brain fog, and brings a real c-Met oncology concern in a population with elevated thyroid-nodule risk.

Hashimoto's Brain Fog in 2026: Where the UK Actually Stands

For most of the twentieth century, the cognitive complaints of thyroid disease were collapsed into the broader description of myxoedema — an older clinical term that captured the sluggish thinking, slowed speech, low mood and memory difficulty of severe hypothyroidism. That language has largely been replaced. Patients today are far more likely to describe their experience as brain fog: a non-specific cluster of forgetfulness, word-finding difficulty, slow processing, attention lapses and a distinctive sense that recall and reasoning have lost their crispness.

The shift in language has not been matched by a shift in clinical priority. Brain fog is still under-recognised in routine endocrine practice. NICE NG145, the UK standard for thyroid disease assessment and management, does not enumerate brain fog as a discrete symptom category. The October 2025 NICE exceptional surveillance reviewed the literature and concluded that the recommendations would not be updated — including the position that levothyroxine remains first-line and that liothyronine (T3) is not routinely recommended alongside or instead of levothyroxine.

That decision is defensible on standard evidence criteria. It is also a source of considerable frustration for the meaningful minority of patients whose TSH is "in range" on levothyroxine monotherapy but whose cognitive symptoms have not resolved. Patient organisations including Thyroid UK and the British Thyroid Foundation have continued to press for a more nuanced UK pathway that allows individualised T3 trials in carefully selected patients, particularly those with DIO2 polymorphism or persistent symptoms after careful T4 optimisation.

Against that policy backdrop, the same self-experimentation culture that has formed around brain fog in Long COVID, menopause, fibromyalgia and ME/CFS has surfaced Dihexa as a candidate for thyroid-related cognitive symptoms. The question this article takes seriously is whether the science supports that step — or whether the answer, for most patients, is the unglamorous one: optimise the T4 dose, check the easy deficiencies, treat the sleep, and only then have a structured T3 conversation with an endocrinologist.

The 2026 Biology of Hashimoto's Brain Fog

Brain fog in autoimmune thyroid disease has multiple contributing mechanisms. The most relevant in 2026 are the following.

Insufficient Brain T3 Despite "Normal" TSH

Levothyroxine is T4. The brain, however, depends on T3 for nuclear receptor binding and for transcription of thyroid-responsive genes including BDNF. Conversion of T4 to T3 in brain tissue depends on local deiodinase enzymes — particularly type 2 deiodinase (DIO2). A common DIO2 Thr92Ala polymorphism is associated with reduced tissue T3 generation and a higher rate of residual symptoms on T4 monotherapy. Normal serum TSH on levothyroxine does not guarantee normal brain T3. This is the dominant biochemical mechanism behind persistent symptoms.

TPO and Thyroglobulin Antibodies in the Brain

Hashimoto's is defined by the presence of thyroid peroxidase (TPO) antibodies and/or thyroglobulin (Tg) antibodies. A 2021 Scientific Reports study using event-related potentials (ERP) and magnetic resonance spectroscopy demonstrated prolonged N200 and P300 latencies and reduced P300 amplitude in Hashimoto's patients versus euthyroid controls, with effects partly independent of thyroid hormone status. Cognitive symptoms correlate with antibody titres in multiple cohorts, suggesting an immune-mediated component beyond simple hormonal deficiency. The current working model is that a subset of TPO antibodies cross-react with central nervous system epitopes and that low-grade neuroinflammation contributes to cognitive symptoms.

The T3-BDNF Axis

Thyroid hormone is one of the most important transcriptional regulators of BDNF in the brain. A 2016 Endocrinology rat study showed that mild developmental thyroid hormone insufficiency reduces activity-dependent BDNF expression and hippocampal plasticity into adulthood. A 2021 mouse primary-neuron study demonstrated that absence of thyroid hormone causes delayed dendritic arborisation in hippocampal neurons through insufficient BDNF expression. In adult humans, hypothyroidism reduces hippocampal volume and blood flow and impairs verbal memory and processing speed — effects that correlate with serum BDNF in several studies. This is a cleaner mechanistic signal than almost any other endocrine-cognitive link.

Hippocampal Volume and Blood Flow

Untreated or undertreated hypothyroidism is associated with measurable reductions in hippocampal volume and cerebral blood flow, particularly in regions central to memory and executive function. Even in treated patients, sub-clinical reductions in hippocampal grey matter density have been demonstrated in several imaging cohorts. These structural changes correlate with cognitive performance and are at least partially reversible with adequate thyroid hormone replacement — supporting the case that thyroid replacement remains the highest-yield intervention for thyroid-related cognitive symptoms.

Vitamin D, Iron, B12 and the Treatable Imitators

A 2018 study in Medicine (Baltimore) reported a significant association between low serum 25(OH)D and cognitive impairment in Hashimoto's patients. Iron-deficiency anaemia, B12 deficiency, folate deficiency and coeliac disease all cluster with autoimmune thyroid disease and all cause cognitive symptoms easily mistaken for thyroid brain fog. Proper assessment of these treatable imitators is the single most undervalued step in Hashimoto's care.

Gut Permeability and Low-Grade Inflammation

An emerging body of evidence ties Hashimoto's to coeliac disease (~5% co-prevalence) and to a broader gut-permeability / low-grade inflammation pattern. Patients with elevated TPO antibodies frequently demonstrate higher CRP, IL-6 and TNF-alpha than antibody-negative controls. Chronic low-grade inflammation independently reduces cognitive performance and may amplify the central effects of antibody activity.

Sleep, Mood and Apparent Brain Fog

Hypothyroidism worsens sleep architecture and increases the prevalence of obstructive sleep apnoea. Depression and anxiety are more common in Hashimoto's than in matched controls. Sleep fragmentation, low mood and anxiety all independently reduce cognitive performance. Any analysis of Hashimoto's brain fog that ignores sleep, mood and the overlap with obstructive sleep apnoea is incomplete.

The simplified picture. Hashimoto's brain fog is a multi-hit phenomenon: insufficient brain T3 reduces BDNF-driven synaptic support, TPO antibodies drive low-grade central inflammation, vitamin D / iron / B12 deficiencies amplify the deficit, hippocampal volume and blood flow fall, and co-existing sleep and mood problems compound the effect. Effective care addresses all of these simultaneously.

The T3-BDNF-HGF Chain: Where Dihexa Enters the Picture

For the Dihexa-specific question, the most relevant molecular story is the three-way link between thyroid hormone, BDNF, and hepatocyte growth factor (HGF). Each of these pathways supports synaptic plasticity, and all three converge on the same downstream endpoint: dendritic spine formation, synaptic strengthening, and maintenance of hippocampal circuit integrity.

Active thyroid hormone (T3) binds nuclear receptors (TR-alpha and TR-beta) and directly upregulates BDNF transcription. BDNF then drives TrkB-dependent dendritic spine maturation. Independently, HGF/c-Met signalling also drives synaptogenesis through the PI-3K/AKT and MAPK pathways — a parallel track that does not depend on thyroid hormone or BDNF directly, but that increases the same cellular output. Peak MET expression in cortex coincides with periods of rapid synaptogenesis in development, the system remains active in adult cortex, and is upregulated in response to synaptic injury or hormonal deficit.

Dihexa — a small-molecule peptide analogue derived from angiotensin IV — is a positive modulator of the HGF/c-Met pathway. Full molecular detail lives on the mechanism of action page. The relevance to Hashimoto's brain fog rests on three points of overlap:

  • Synaptogenesis as the direct inverse of hippocampal deficit. Hypothyroidism reduces dendritic arborisation and synapse density in hippocampal CA1. Dihexa promotes dendritic spine formation in cell culture within hours of exposure. The end-points are symmetrical. The unresolved question is whether spine induction observed in cell culture translates to measurable cognitive benefit in an antibody-positive human brain.
  • A parallel route to synaptic support that does not require T3. In patients with documented DIO2 polymorphism, malabsorption of oral T4, or restricted access to T3 trials under NICE NG145, a pathway that supports synaptic plasticity without adding thyroid hormone is conceptually interesting. The operative word is conceptually; the clinical data to back up that reasoning do not exist.
  • Regional expression of c-Met maps onto the deficit. The hippocampus, prefrontal cortex and anterior cingulate — the regions most affected by Hashimoto's-associated cognitive dysfunction — are also among those with the highest density of c-Met receptors in the adult brain. A pharmacological signal at c-Met therefore lands in the right anatomical place.

This is the mechanistic case for considering Dihexa in Hashimoto's brain fog. The rest of this article is about why the shape of the mechanism is not the same as evidence for the intervention — and why the c-Met biology raises a thyroid-specific safety question that does not arise in most other indications.

Optimise Levothyroxine First: The Only Evidence-Based Starting Point

Any honest review of Hashimoto's brain fog has to begin with the licensed treatment that addresses the root cause: levothyroxine optimisation. NICE NG145 sets out a structured pathway for diagnosis, dose titration and monitoring. Several practical points deserve emphasis for cognitive symptoms specifically.

  • Dose optimisation, not just "in-range" TSH. The reference range for TSH is wide (typically 0.4–4.0 mIU/L). The dose that resolves cognitive symptoms is often at the lower TSH end of the range for that individual. Persistent fog at a TSH of 3.5 may improve with a dose adjustment that brings TSH to 1.0–2.0. This is a conversation for a GP or endocrinologist, not a peptide forum.
  • Absorption matters more than people realise. Levothyroxine absorption is reduced by food, coffee, calcium-containing supplements, iron, proton pump inhibitors and several common medications. Taking levothyroxine on an empty stomach with water, separating it from other tablets by at least an hour, and avoiding coffee for 30–60 minutes after dosing improves cognitive symptoms in a meaningful subset of patients without any dose change.
  • Brand consistency. Bioequivalence of levothyroxine brands in the UK is not perfect, and a small subset of patients are sensitive to brand switches. A request for consistent dispensing of the same brand is reasonable and is supported by MHRA guidance.
  • T3 in selected cases. NICE NG145 does not routinely recommend liothyronine but acknowledges a research question around DIO2-polymorphism patients and persistent symptoms. The October 2025 NICE exceptional surveillance reaffirmed this stance. A small but structured T3 trial under endocrinology supervision is appropriate for carefully selected patients with persistent symptoms despite optimised T4. NHS England Regional Medicines Optimisation Committee guidance constrains routine initiation; specialist supervision is required.
  • NDT is not on the NHS. Natural desiccated thyroid (Armour, Erfa) is not a licensed product in the UK and is not available through the NHS. Some private endocrinologists prescribe it on a named-patient basis. The British Thyroid Association and BTF both caution against unsupervised use.
  • Antibody monitoring is not routine after diagnosis. Once Hashimoto's is established, NICE does not recommend repeat antibody testing because results do not change management. This is a frequent source of patient frustration; it reflects the limited utility of antibody titres as a clinical decision-making tool, not dismissal of antibody-driven biology.

For the majority of UK patients presenting with Hashimoto's-related cognitive symptoms, structured optimisation of levothyroxine and correction of the common deficiencies resolves enough of the symptom burden that experimental interventions become unnecessary. The mechanistic logic is cleaner than for any peptide: you are correcting the hormone deficit whose cause produced the symptom.

Dihexa is not a substitute for levothyroxine. It is, at best, an experimental adjunct to consider after levothyroxine has been optimised, T3 trial has been considered and either accepted or declined under specialist guidance, deficiencies are corrected, lifestyle factors are in place, and residual cognitive symptoms persist — and even then, only after a frank conversation with a clinician.

Hashimoto's Encephalopathy (SREAT): The Important Distinction

Within the broader umbrella of "thyroid brain symptoms" sits a genuinely distinct clinical entity that deserves explicit mention: Hashimoto's encephalopathy (HE), also termed steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT).

A 2025 Biomedicines review and a parallel 2025 Frontiers in Psychiatry review emphasise the diagnostic difficulty of this condition. HE presents with cognitive impairment, seizures, stroke-like episodes, psychiatric disturbance and altered consciousness, typically in the context of elevated TPO antibodies and either euthyroid or hypothyroid status. It is steroid-responsive — corticosteroids are first-line — but recent reviews have noted that cognitive deficits can persist beyond two years of follow-up despite prolonged steroid therapy.

HE is not the same as Hashimoto's brain fog. It is rare, it is a neurological emergency, and it requires inpatient or specialist assessment. Anyone whose "brain fog" is accompanied by seizures, hallucinations, sudden personality change, focal neurological signs, stroke-like episodes or rapid cognitive deterioration is not a candidate for self-experimentation with any unlicensed compound. They are a candidate for an urgent neurology referral.

The relevance to Dihexa is twofold. First, the existence of HE is a reminder that autoimmune thyroid disease can produce neurological harm independent of thyroid hormone level. Second, the persistence of cognitive deficits in HE despite steroid treatment shows how stubbornly antibody-driven cognitive damage can resist standard immunomodulation — a humbling backdrop for any claim that a synaptogenic peptide will reverse it.

The Fosgonimeton Parallel and the Limits of Mechanism

Because no controlled human trial of Dihexa in thyroid disease exists, the most informative clinical-stage comparator is fosgonimeton (ATH-1017): a small-molecule positive modulator of the HGF/MET system developed by Athira Pharma. Fosgonimeton is not Dihexa, but it shares the core mechanism of amplifying HGF/c-Met signalling, and unlike Dihexa it has been tested in humans. The full story is on the dedicated fosgonimeton page.

What fosgonimeton brings to the thyroid question is a sobering lesson in the gap between mechanism and clinical outcome. The active metabolite enhances the HGF/MET system, demonstrates procognitive effects in animal models of neuroinflammation-driven cognitive impairment, and was well-tolerated in Phase 1 human studies. The Phase 3 LIFT-AD trial in Alzheimer's disease reported out in 2024 and did not meet its primary cognitive endpoint. The programme was subsequently refocused.

The lesson for Hashimoto's brain fog is direct. A well-validated, well-tolerated, mechanistically coherent approach to the HGF/MET system failed to produce a measurable clinical win in a cognitively-impaired population. Dihexa, whose human data are sparser than fosgonimeton's and whose safety follow-up in chronic use is effectively absent, inherits that cautionary story. Mechanism-first reasoning is seductive; clinical endpoints in cognition are humbling.

Thyroid-Specific Risks: c-Met, Goitre and Nodular Disease

The general Dihexa safety discussion is on the side effects and risks page. Several risks become more pointed in the context of autoimmune thyroid disease.

c-Met Activation and Thyroid Cancer Risk

HGF/c-Met signalling is oncogenically relevant across a range of tumour types, and the thyroid is one of the cleaner examples. Papillary thyroid cancer — the most common thyroid malignancy — frequently demonstrates c-Met overexpression, and HGF/MET signalling has been linked to invasiveness and lymph node metastasis. Anaplastic thyroid cancer and follicular thyroid cancer also express c-Met. Hashimoto's patients have an elevated baseline risk of thyroid nodules and a modestly elevated lifetime risk of papillary thyroid cancer. Pharmacologically amplifying HGF/c-Met in someone with undiagnosed nodular disease is a meaningfully uncertain risk. This is the single most important thyroid-specific safety concern.

Goitre and Diffuse Thyroid Disease

Hashimoto's frequently produces a diffuse goitre or, less commonly, a multinodular pattern. Any pharmacological intervention that could in principle alter the trophic environment of the thyroid gland is unwelcome in this setting without a controlled assessment. No such assessment exists for Dihexa.

Interaction with Thyroid Hormone Replacement

No controlled pharmacokinetic study has examined the interaction between Dihexa and levothyroxine, liothyronine, NDT, propylthiouracil, carbimazole, or any thyroid drug. The interaction profile is not small; it is uncharacterised. In any patient already on thyroid hormone replacement, adding an unlicensed peptide without clinician oversight makes future dose adjustment of licensed therapy considerably harder to interpret.

Mood, Sleep and Symptom Variability

Community reports of Dihexa frequently mention vivid dreams, disturbed sleep and, in a minority, mood changes. In a population where sleep is already fragmented and depression and anxiety are frequently co-existing, the margin for destabilisation is smaller than in cognitively-healthy younger users. Any worsening of sleep, mood or thyroid symptoms in the first week of a trial should be treated as a stop signal.

Masking Treatable Contributors

The most consequential risk in thyroid brain fog is the one shared with menopause and Long COVID: an unlicensed compound that produces a non-specific lift in perceived clarity can delay an assessment that would otherwise pick up sub-optimal levothyroxine dosing, iron deficiency, B12 deficiency, vitamin D deficiency, coeliac disease, sleep apnoea or depression. These are all genuine, correctable drivers of thyroid-related cognitive symptoms. Treating them is cheap, safe, effective, and available on the NHS. Missing them costs years.

Strong Placebo Effect and Symptom Variability

Hashimoto's symptoms wax and wane with antibody fluctuation, infection, stress, sleep, menstrual cycle and seasonal change. Placebo response in thyroid-symptom trials is routinely 20–40% for fatigue and similar for subjective cognitive measures. Any uncontrolled self-trial of an unlicensed peptide at a symptom peak is structurally biased towards reading random regression to the mean as treatment effect.

Who Should Not Consider Dihexa for Hashimoto's Brain Fog

  • Anyone with a personal or family history of thyroid cancer (papillary, follicular, anaplastic, medullary or Hurthle cell).
  • Anyone with multinodular goitre, indeterminate or suspicious thyroid nodules on ultrasound (TIRADS 3 or above), or pending fine-needle aspiration cytology.
  • Anyone with a personal or family history of breast, ovarian, lung, gastric or other hormone-sensitive cancers given the broader c-Met oncology profile.
  • Anyone with active or suspected Hashimoto's encephalopathy / SREAT; this requires urgent neurology assessment.
  • Anyone with active Graves' disease, thyroid storm, or recently treated hyperthyroidism not yet stabilised.
  • Anyone pregnant, breastfeeding, or planning conception — thyroid hormone requirements rise sharply in pregnancy and uncontrolled experimentation in this window is hazardous.
  • Anyone with a diagnosed bipolar or psychotic-spectrum condition (autoimmune thyroid disease is associated with both, and peptide-induced mood destabilisation is a documented community concern).
  • Anyone whose thyroid status has not been formally assessed, ideally with TSH, free T4, free T3, TPO and Tg antibodies, ferritin, B12, folate, vitamin D, coeliac antibodies and a fasting glucose / HbA1c.
  • Anyone on multiple licensed medications for thyroid, mood, cardiovascular or metabolic conditions without clinician oversight of an unlicensed addition.

What the Evidence Actually Supports for Hashimoto's Brain Fog in 2026

For balance — and because this is where most patients should start — here is what the 2026 evidence base genuinely supports.

  • GP assessment and structured levothyroxine optimisation. Aim for the symptom-resolving dose rather than the mid-range TSH. The NICE NG145 pathway is the basis for this conversation.
  • Absorption-aware dosing. Empty stomach, 30–60 minute fast, separation from coffee, calcium, iron and PPIs.
  • Endocrinology referral for persistent symptoms. Patients with persistent fog despite optimised T4 should have a structured endocrinology review for consideration of T3 trial under specialist supervision, in line with NICE NG145 and the patient-organisation-supported case for individualised assessment.
  • Rule out imitators. Ferritin, B12, folate, vitamin D, fasting glucose / HbA1c, coeliac antibodies, sleep apnoea screening. Correct deficiencies before considering any experimental intervention.
  • Treat mood and anxiety. Depression and anxiety in Hashimoto's respond to evidence-based treatment and strongly improve perceived cognitive symptoms. See Dihexa for depression & mood for the synaptogenic-hypothesis context.
  • Aerobic and resistance exercise. Both raise BDNF independently of thyroid hormone and have the best effect sizes of any non-pharmacological intervention for midlife cognition.
  • Sleep. Protected sleep timing, consistent schedule, limiting evening alcohol, screening for obstructive sleep apnoea where snoring or witnessed apnoeic episodes are reported.
  • Cognitive load and pacing. External scaffolds (lists, calendars, voice notes), avoiding self-criticism for cognitive lapses, and structured cognitive routines work in autoimmune disease as well as they work elsewhere.
  • Vetted patient-facing resources. The British Thyroid Foundation, Thyroid UK and the NHS underactive thyroid pages are reliable UK-specific resources.

If Someone Were Considering It: Practical Realities

This section is descriptive, not prescriptive. There is no validated protocol for Dihexa in Hashimoto's because there is no trial. What follows is what self-experimenters report and the realities they describe — together with caveats that should temper any inference.

  • No thyroid-specific dose. Community dosing ranges (covered in the Dihexa dosage guide) were derived from cognitive-enhancement use in predominantly male, euthyroid cohorts. Pharmacokinetics in hypothyroid and Hashimoto's populations are not characterised.
  • Cycling and short trials. Short cycles with clear on/off periods are generally preferred to continuous use, both to limit sustained c-Met activation and to give enough off-period to evaluate any genuine effect versus placebo or concurrent thyroid dose adjustments. See the Dihexa Review 2026 for community-reported cycling approaches.
  • Stacking is not the answer. Adding Dihexa to an already complex thyroid stack (levothyroxine, T3, NDT, selenium, iron, vitamin D, mood medication, sleep aids) creates an interaction landscape no one can interpret meaningfully. The general stacking guide cautions explicitly against complex combinations without clinician oversight.
  • Track and rule out placebo. Thyroid symptoms fluctuate week to week and respond to sleep, infection, stress and menstrual cycle. Any intervention tried during a symptom-peak week looks effective in the subsequent normal-variance dip. Brief structured symptom diaries covering sleep, mood, cognitive self-ratings and energy levels are the minimum self-assessment rigour for an unlicensed peptide trial.
  • Re-check thyroid function before and after. TSH, free T4 and free T3 at baseline and after any structured trial period, ideally at the same time of day and with the same lab. Unexplained TSH suppression or biochemical hyperthyroidism is a reason to stop immediately.
  • Stop at the first adverse signal. Worsening palpitations, tremor, heat intolerance, new neck swelling, voice change, unexpected weight loss, unusual headaches, or mood destabilisation are all reasons to stop and seek clinical review.

None of this should be read as endorsement. The strongest practical advice for Hashimoto's brain fog in 2026 is the one that applies before any peptide conversation: get the levothyroxine dose right, fix the easy deficiencies, sleep properly, and consider T3 with an endocrinologist where indicated. That is the evidence-based pathway.

The Bottom Line in 2026

Hashimoto's brain fog is real, biological, and rooted in a combination of insufficient brain T3, antibody-driven low-grade inflammation, reduced hippocampal neurogenesis and synaptic plasticity, vitamin and mineral deficiencies, and overlapping sleep and mood problems. The dominant intervention — with by far the largest evidence base — is optimised thyroid hormone replacement, with T3 trial under specialist supervision in carefully selected non-responders. Deficiency correction, sleep and mood treatment, and structured cognitive support stack on top.

Dihexa, with its direct activation of the HGF/c-Met spine-formation pathway, is one of the few small molecules whose mechanism plausibly addresses part of the underlying deficit. The catch is the same as in every other indication on this site: there is no published, registered clinical trial of Dihexa in any thyroid population. The closest clinical-stage relative (fosgonimeton) confirmed feasibility of HGF/MET modulation in humans but missed its Phase 3 cognitive endpoint. Mechanistic plausibility is necessary but not sufficient — and the c-Met / papillary thyroid cancer biology gives Hashimoto's patients one extra reason to pause.

For the majority of UK Hashimoto's patients, the honest reading of the 2026 evidence is this. Levothyroxine optimisation first, deficiency correction second, T3 trial third under endocrine oversight where indicated, and research chemicals essentially last — if at all. Dihexa is biologically interesting and clinically unproven. The first call should be a GP appointment with a request for a full thyroid antibody panel, not a peptide vendor.

If you are struggling with thyroid symptoms: Speak to your GP about a full thyroid assessment including TSH, free T4, free T3, TPO and thyroglobulin antibodies, ferritin, B12, folate and vitamin D. The NHS underactive thyroid hub, British Thyroid Foundation and Thyroid UK list patient-facing resources. For mental health support, Samaritans are free, 24/7 on 116 123. In a life-threatening emergency, call 999 or go to A&E.

Frequently Asked Questions

Has Dihexa been clinically trialled in Hashimoto's or hypothyroidism?

No. As of June 2026 there is no registered or completed clinical trial of Dihexa in Hashimoto's thyroiditis, primary or secondary hypothyroidism, subclinical hypothyroidism, Graves' disease, Hashimoto's encephalopathy or any thyroid-related cognitive symptom. Self-experimentation reports are not clinical evidence. See the research and studies page for the full state of the Dihexa evidence base.

My TSH is normal but I still have brain fog — what now?

First, check the TSH target with your prescribing clinician — many patients with persistent symptoms benefit from a TSH closer to 1.0–2.0 than 3.5–4.0. Second, check absorption (food, coffee, calcium, iron, PPI timing). Third, screen for ferritin, B12, folate, vitamin D, coeliac, and sleep apnoea. Fourth, if symptoms persist on properly optimised T4 and after deficiency correction, ask about referral to an endocrinologist for consideration of a structured T3 trial under NICE NG145.

Could Dihexa replace levothyroxine?

No. Levothyroxine addresses the systemic loss of thyroid hormone, which has effects on heart, metabolism, gut, reproductive function, bone, mood and brain. Dihexa addresses one downstream cellular process (synapse formation). Stopping levothyroxine in the hope that a peptide will compensate is biologically incoherent and clinically dangerous, particularly in pregnancy.

What about stacking Dihexa with levothyroxine and T3?

No formal interaction study exists. Both thyroid hormone and Dihexa modulate BDNF and synaptic plasticity, so a combined effect is biologically plausible but uncharacterised. The larger issue is that adding an unlicensed peptide to a licensed thyroid regime complicates dose interpretation and may produce TSH or symptom changes that are difficult to attribute. Any patient considering combined use should raise it explicitly with their thyroid prescriber.

I have positive TPO antibodies but my TSH is normal — should I take Dihexa?

No. Antibody-positive euthyroid status (sometimes called Hashimoto's without hypothyroidism) is a recognised category. Cognitive symptoms in this group are real but the right response is structured assessment for treatable contributors (vitamin D, B12, iron, coeliac, sleep, mood), monitoring of thyroid function, and only then specialist consideration. Pharmacologically amplifying c-Met in a patient with positive thyroid antibodies and unknown nodular status carries an avoidable risk.

Is Hashimoto's brain fog a sign of dementia?

Not usually. For most patients, Hashimoto's brain fog is a treatment-responsive cluster of cognitive changes tied to thyroid hormone status, antibody activity, and the treatable imitators. Persistent and progressive cognitive decline, particularly with disorientation, loss of established skills, or self-care impairment, is a reason for prompt clinical assessment and not for unlicensed peptide use. See our companion review Dihexa for MCI & brain aging for the dementia-risk context.

What does NICE NG145 actually say about T3?

NICE NG145 recommends levothyroxine as first-line for primary hypothyroidism and does not routinely recommend liothyronine (T3) alone or in combination, citing insufficient evidence of benefit over T4 monotherapy and uncertain long-term safety. The October 2025 NICE exceptional surveillance review reaffirmed this position. NHS England regional medicines guidance further constrains routine initiation. T3 trials may be considered by specialists for carefully selected patients with persistent symptoms despite optimised T4.

I have a history of thyroid cancer — can I try Dihexa?

This is a strong contraindication in our editorial view. HGF/c-Met signalling is oncogenically relevant in papillary, follicular, anaplastic and other thyroid cancers, and Dihexa is a pharmacological activator of that pathway. Anyone with personal or family history of thyroid cancer or with unresolved thyroid nodules should avoid unlicensed peptides of this class and discuss evidence-based cognitive-symptom alternatives with their endocrinology team.

What about Graves' disease and hyperthyroid brain fog?

Graves' disease, the autoimmune cause of hyperthyroidism, also produces cognitive symptoms — though clinically distinct from Hashimoto's (anxiety-tinged, with concentration and short-term memory difficulty). The same overarching principle applies: treat the underlying thyroid disease first with carbimazole, propylthiouracil, radioactive iodine or thyroidectomy as appropriate, address sleep and mood, and only consider experimental compounds long after the thyroid status is stable. Dihexa has not been studied in Graves' disease either.

External Authoritative Sources Cited

Editorial statement: This article is part of a rolling 2026 clinical-context review series examining where Dihexa sits in the evidence hierarchy for specific indications. We are not clinicians. This page is for education and is not medical advice. See the About page for our editorial approach and the disclaimer for legal scope.